Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virt...
Israel is set to become the first country in the world to administer a fourth COVID-19 vaccine, which would give "greater protection in the face of Omicron." The first eligible group to receive the vaccine will be people age 60 and older, as well as the immunocompromised and medical personnel...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips California-based Vaxart (NASDAQ: VXRT ) is a biopharmaceutical company that’s known for one relentless business focus: making vaccines. As you would expect, the emergence of Covid-19 last year made VXRT st...
Vaxart (VXRT +8.1%) shares are up today -- the third day in a row -- as the company continues to benefit from a plan to test the reactivity of its COVID-19 oral vaccine candidate against the Omicron variant. The company says that it will start two studies next month. One will use mucosal and ...
FinancialBuzz.com News Commentary New York, NY (12/17/2021) – The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma, a top health advisor t...
Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study Oral tablet’s immunogenicity profile suggests it may provide cross-protection against SARS-CoV-2 variants, including Omicron SOUTH SAN FRANCI...
Vaxart is the oral vaccine developer with COVID, RSV, HPV, influenza and Norovirus candidates in its pipeline. The company faces litigation after allegedly misinforming the market about being selected for Operation Warp Speed last year. A COVID vaccine success is not out of the qu...
Shares of the COVID-19 vaccine makers Pfizer (NYSE: PFE) , Ocugen (NASDAQ: OCGN) , and Vaxart (NASDAQ: VXRT) are all moving in the wrong direction today. Specifically, Pfizer's stock is down by approximately 4%, Ocugen's equity is in the red by 5.64%, and Vaxart's sh...
COVID-19 vaccine makers have dragged the biotech space in morning hours after Vermont Senator Bernie Sanders criticized Moderna (MRNA -13.5%) and Pfizer (PFE -2.8%) in a tweet on Sunday. “Last week, 8 investors in Pfizer and Moderna became $10 billion richer as news about the Omicron v...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite omicron variant chatter propping up even relatively obscure biotech companies , Vaxart (NASDAQ: VXRT ) can’t seem to get in on the conversation. VXRT stock is down 9% today as it appears to be leveling...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...